SARS-CoV-2 humoral responses following booster BNT162b2 vaccination in patients with B-cell malignancies,American Journal of Hematology

当前位置： X-MOL 学术 › Am. J. Hematol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

SARS-CoV-2 humoral responses following booster BNT162b2 vaccination in patients with B-cell malignancies
American Journal of Hematology ( IF 10.1 ) Pub Date : 2022-07-24 , DOI: 10.1002/ajh.26669
Evangelos Terpos ₁ , Despina Fotiou ₁ , Vangelis Karalis ₂ , Ioannis Ntanasis-Stathopoulos ₁ , Aimilia D Sklirou ₃ , Maria Gavriatopoulou ₁ , Panagiotis Malandrakis ₁ , Vassiliki A Iconomidou ₃ , Efstathios Kastritis ₁ , Ioannis P Trougakos ₃ , Meletios A Dimopoulos ₁

Affiliation

Patients with B-cell malignancies have suboptimal immune responses to SARS-CoV-2 vaccination and are a high-risk population for severe COVID19 disease. We evaluated the effect of a third booster BNT162b2 vaccine on the kinetics of anti- SARS-CoV-2 neutralizing antibody (NAbs) titers in patients with B-cell malignancies. Patients with NHL (n = 54) Waldenström's macroglobulinemia (n = 90) and chronic lymphocytic leukemia (n = 49) enrolled in the ongoing NCT04743388 study and compared against matched healthy controls. All patient groups had significantly lower NAbs compared to controls at all time points. 1 month post the third dose (M1P3D) NAbs increased significantly compared to previous time points (median NAbs 77.9%, p < .05 for all comparisons) in all patients. NAbs ≥ 50% were seen in 59.1% of patients, 34.5% of patients with suboptimal responses post-second dose, elicited a protective NAb titer ≥50%. Active treatment, rituximab, and BTKi treatment were the most important prognostic factors for a poor NAb response at 1MP3D; only 25.8% of patients on active treatment had NAbs ≥ 50%. No significant between-group differences were observed. Patients with B-cell malignancies have inferior humoral responses against SARS-CoV-2 and booster dose enhances the NAb response in a proportion of these patients.

中文翻译：

B 细胞恶性肿瘤患者加强 BNT162b2 疫苗接种后的 SARS-CoV-2 体液反应

B细胞恶性肿瘤患者对SARS-CoV-2疫苗的免疫反应欠佳，是严重COVID19疾病的高危人群。我们评估了第三种 BNT162b2 加强疫苗对 B 细胞恶性肿瘤患者抗 SARS-CoV-2 中和抗体 (NAb) 滴度动力学的影响。NHL ( n = 54) Waldenström 巨球蛋白血症 ( n = 90) 和慢性淋巴细胞白血病 ( n = 49) 患者参加了正在进行的 NCT04743388 研究，并与匹配的健康对照组进行比较。在所有时间点，与对照组相比，所有患者组的 NAb 均显着降低。第三次给药后 1 个月 (M1P3D) NAb 与之前的时间点相比显着增加（中位 NAb 为 77.9%，p < .05 对于所有比较）在所有患者中。NAb ≥ 50% 见于 59.1% 的患者，34.5% 的患者在第二次给药后反应不佳，导致保护性 NAb 滴度≥50%。积极治疗、利妥昔单抗和 BTKi 治疗是 1MP3D 时 NAb 反应不佳的最重要预后因素；只有 25.8% 接受积极治疗的患者 Nabs ≥ 50%。未观察到显着的组间差异。B 细胞恶性肿瘤患者对 SARS-CoV-2 的体液反应较差，加强剂量可增强部分患者的 NAb 反应。

更新日期：2022-07-24

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南11